• Analysis of over 16,000 patients switched to HADLIMA® from HUMIRA® (adalimumab) showed a 1.3% switchback rate over a 12-month follow-up period1
• Data demonstrated the switching cohort had an average first-year per-patient pharmacy cost decrease of $8,100 across all indications in the analysis1
• The switch resulted in $132 million total estimated savings to the Veterans Affairs Healthcare System1

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.